Markets:

Overview

News

Currencies

International

Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

14.66 -0.06 (-0.41%)

Streaming Delayed Price Updated: 10:15 AM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

7 Chinese Stocks to Sell While You Still Can ↗

September 02, 2022

These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure

Via InvestorPlace

Week in Review: Hansoh In-licenses Endometriosis/Fibroid Therapy in $170 Million Deal ↗

August 13, 2022

Other funding deals for drug discovery, R&D, gene editing.

Via Talk Markets

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 09, 2022

Via Benzinga

Goldman Sachs Maintains Neutral Rating for HUTCHMED: Here's What You Need To Know ↗

August 09, 2022

Goldman Sachs has decided to maintain its Neutral rating of HUTCHMED (China) (NASDAQ:HCM) and raise its price target from $14.00 to $16.00. Shares of HUTCHMED (China) are trading down 5.74% over the...

Via Benzinga

Recap of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 08, 2022

Via Benzinga

AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting ↗

August 08, 2022

Via Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial ↗

August 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate ↗

July 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

HUTCHMED Highlights SAVANNAH Trial Data Of Savolitinib Combo In Lung Cancer Setting ↗

July 13, 2022

Via Benzinga

83 Biggest Movers From Yesterday ↗

June 09, 2022

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 08, 2022

Via Benzinga

HUTCHMED (China) Limited (NASDAQ:HCM) Investor Alert: Investigation over Potential Wrongdoing ↗

June 08, 2022

San Diego, CA -- (SBWIRE) -- 06/08/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at HUTCHMED (China) Limited.

Via SBWire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm

May 27, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm

May 26, 2022

From The Schall Law Firm

Via Business Wire

EQUITY ALERT: Rosen Law Firm Encourages HUTCHMED (China) Limited Investors with Losses to Inquire About Class Action Investigation – HCM

May 26, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

38 Stocks Moving In Friday's Mid-Day Session ↗

May 20, 2022

Gainers Leju Holdings Limited (NYSE: LEJU) surged 27.8% to $4.0413.

Via Benzinga

20 Stocks Moving in Friday's Pre-Market Session ↗

May 20, 2022

Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 28.1% to $0.1550 in pre-market trading. Exicure said in Form4 filing a director bought 1,472,126 shares at average price of $0.19 per share.

Via Benzinga

76 Biggest Movers From Yesterday ↗

May 19, 2022

Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to...

Via Benzinga

NASDAQ:HCM Shareholder Notice: Investigation over Possible Securities Laws Violations by HUTCHMED (China) Limited ↗

May 16, 2022

San Diego, CA -- (SBWIRE) -- 05/16/2022 -- HUTCHMED (China) Limited is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas ↗

May 13, 2022

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The...

Via Benzinga

Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund ↗

May 07, 2022

One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in...

Via Talk Markets

66 Biggest Movers From Yesterday ↗

May 03, 2022

Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged...

Via Benzinga

HFCAA News: 128 Chinese Stocks the SEC Could Delist ↗

May 05, 2022

The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 02, 2022

Via Benzinga

31 Stocks Moving In Monday's Mid-Day Session ↗

May 02, 2022

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48...

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower; US Factory Growth Slows In April ↗

May 02, 2022

U.S. stocks traded mostly lower this morning, with the Dow Jones tumbling around 100 points on Monday.

Via Benzinga

U.S. FDA Rejects HUTCHMED's New Drug Application For Surufatinib In Neuroendocrine Tumors ↗

May 02, 2022

HUTCHMED (China) Limited (Nasdaq: HCM) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Surufatinib for the treatment of...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 02, 2022

Via Benzinga

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products ↗

April 23, 2022

Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

All News about HUTCHMED (China) Limited - American Depositary Shares

Starting at $3.75/week.

Subscribe Today